Prosensa (NASDAQ: RNA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Insider & Institutional Ownership
36.0% of Voyager Therapeutics shares are held by institutional investors. 8.0% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Prosensa and Voyager Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Voyager Therapeutics has a consensus target price of $26.90, indicating a potential upside of 50.20%. Given Voyager Therapeutics’ higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Prosensa.
Valuation & Earnings
This table compares Prosensa and Voyager Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Voyager Therapeutics||$14.22 million||39.61||-$40.19 million||($2.84)||-6.31|
Prosensa has higher earnings, but lower revenue than Voyager Therapeutics. Prosensa is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Prosensa and Voyager Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Voyager Therapeutics beats Prosensa on 8 of the 10 factors compared between the two stocks.
Prosensa Company Profile
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. The Company’s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company’s platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
Receive News & Ratings for Prosensa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prosensa and related companies with MarketBeat.com's FREE daily email newsletter.